NELL1 is a recently described antigen seen in membranous glomerulopathy, which has been associated with malignancy. A recent study linked Lipoic Acid supplementation with membranous glomerulopathy. In this letter to the editor, medication use was examined in 115 patients with NELL1 positive membranous glomerulopathy and 200 patients with membranous glomerulopathy of other types. In the NELL1 positive group, 15 patients had active Lipoic Acid use, while no Lipoic Acid supplementation was seen in the non-NELL1 membranous group. In addition to a malignancy workup in patients diagnosed with NELL1 positive membranous glomerulopathy, patients should also be asked about Lipoic Acid supplementation.
Quick note: This post is to be used for informational purposes only and does not constitute medical or health advice. Each person should consult their own doctor with respect to matters referenced. Arkana Laboratories assumes no liability for actions taken in reliance upon the information contained herein.